5.93
-0.235(-3.81%)
Currency In USD
| Previous Close | 6.16 |
| Open | 6.09 |
| Day High | 6.27 |
| Day Low | 5.91 |
| 52-Week High | 10 |
| 52-Week Low | 2.54 |
| Volume | 561,814 |
| Average Volume | 736,158 |
| Market Cap | 441.5M |
| PE | -5.39 |
| EPS | -1.1 |
| Moving Average 50 Days | 4.66 |
| Moving Average 200 Days | 4.78 |
| Change | -0.24 |
If you invested $1000 in Corvus Pharmaceuticals, Inc. (CRVS) since IPO date, it would be worth $415.79 as of September 08, 2025 at a share price of $5.925. Whereas If you bought $1000 worth of Corvus Pharmaceuticals, Inc. (CRVS) shares 5 years ago, it would be worth $1,773.95 as of September 08, 2025 at a share price of $5.925.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:01 PM GMT
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the c
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Trial will be conducted by Angel Pharma and will study 12-week dosing of soquelitinib in patients with moderate-to-severe atopic dermatitisSOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
GlobeNewswire Inc.
Jun 11, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sc